https://www.mynewsdesk.com/se/bristol-myers_squibb Mynewsdesk RSS - pressmeddelanden, nyheter och blogginlägg. https://www.mynewsdesk.com/se/bristol-myers_squibb https://www.mynewsdesk.com/assets/graphics/logos/logo-small-9892f98564f91864075bd14001f8470f2f9bf254729c37044b4b1ac9b0db6b40.png 128 23 sv 15 Mon, 29 Sep 2025 07:12:28 +0200 https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/vaerldshjaertdagen-ny-rapport-visar-att-sverige-halkar-efter-i-diagnos-av-aerftlig-hjaertsjukdom-3407098?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/vaerldshjaertdagen-ny-rapport-visar-att-sverige-halkar-efter-i-diagnos-av-aerftlig-hjaertsjukdom-3407098?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Mon, 02 Jun 2025 08:50:00 +0200 https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/europeiska-kommissionen-godkaenner-subkutan-beredning-av-opdivo-nivolumab-foer-behandling-av-flera-solida-tumoerer-3389457?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/europeiska-kommissionen-godkaenner-subkutan-beredning-av-opdivo-nivolumab-foer-behandling-av-flera-solida-tumoerer-3389457?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Mon, 31 Mar 2025 08:00:00 +0200 Det positiva CHMP-utlåtandet baseras på resultat från CheckMate-67T-studien, samt ytterligare data som visade jämförbar farmakokinetik, säkerhetsprofil och effekt mellan subkutan och intravenös användning av nivolumab. https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/positivt-chmp-utlaatande-foer-subkutan-beredning-med-opdivo-nivolumab-foer-behandling-av-flera-solida-tumoerer-3378223?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/positivt-chmp-utlaatande-foer-subkutan-beredning-med-opdivo-nivolumab-foer-behandling-av-flera-solida-tumoerer-3378223?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Mon, 24 Mar 2025 08:48:00 +0100 https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/evris-michalopoulos-ny-vd-foer-bms-i-sverige-och-norden-3376022?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/evris-michalopoulos-ny-vd-foer-bms-i-sverige-och-norden-3376022?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Wed, 19 Feb 2025 10:14:15 +0100 Akademiska sjukhuset i Uppsala flyttar cancervården närmare patienten - i ett köpcentrum i Gränbystaden. Nu finns rapport publicerad om inledande resultat. https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/ny-rapport-visar-betydande-foerdelar-med-cancervaard-naermare-patienten-3370741?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/ny-rapport-visar-betydande-foerdelar-med-cancervaard-naermare-patienten-3370741?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Thu, 05 Sep 2024 08:00:00 +0200 Långtidsdata från EXPLORER-LTE-kohorten av MAVA-LTE-studien, visar varaktig och bibehållen förbättring för patienter med symtomatisk HOCM NYHA-klass II och III. https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/laangtidsuppfoeljning-fraan-fas-3-studie-av-camzyos-mavakamten-visar-varaktiga-foerbaettringar-av-ekokardiografiska-maatt-biomarkoerer-och-symtom-hos-patienter-med-symtomatisk-obstruktiv-hypertrofisk-kardiomyopati-hocm-3340872?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/laangtidsuppfoeljning-fraan-fas-3-studie-av-camzyos-mavakamten-visar-varaktiga-foerbaettringar-av-ekokardiografiska-maatt-biomarkoerer-och-symtom-hos-patienter-med-symtomatisk-obstruktiv-hypertrofisk-kardiomyopati-hocm-3340872?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Mon, 24 Jun 2024 11:04:22 +0200 https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/nt-raadet-rekommenderar-breyanzi-lisokabtagen-maraleucel-foer-behandling-av-aggressiva-b-cellslymfom-i-andra-och-tredje-linjen-3331310?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/nt-raadet-rekommenderar-breyanzi-lisokabtagen-maraleucel-foer-behandling-av-aggressiva-b-cellslymfom-i-andra-och-tredje-linjen-3331310?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Tue, 04 Jun 2024 13:16:24 +0200 Bristol Myers Squibb meddelar idag resultat från 5-årsuppföljningen av fas 3-studien CheckMate –9LA som visar varaktiga, långsiktiga överlevnadsfördelar med Opdivo plus Yervoy (ipilimumab) i kombination med två cykler av kemoterapi, jämfört med enbart kemoterapi som första linjens behandling av patienter med metastaserad icke-småcellig lungcancer NSCLC. https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/femaarsdata-fraan-checkmate-9la-studien-visar-att-opdivo-plus-yervoy-och-kemoterapi-foerbaettrar-oeverlevnaden-hos-patienter-med-tidigare-obehandlad-metastaserad-icke-smaacellig-lungcancer-jaemfoert-med-enbart-kemoterapi-3327584?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/femaarsdata-fraan-checkmate-9la-studien-visar-att-opdivo-plus-yervoy-och-kemoterapi-foerbaettrar-oeverlevnaden-hos-patienter-med-tidigare-obehandlad-metastaserad-icke-smaacellig-lungcancer-jaemfoert-med-enbart-kemoterapi-3327584?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Wed, 29 May 2024 17:48:30 +0200 https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/eu-kommissionen-godkaenner-bristol-myers-squibbs-opdivo-nivolumab-i-kombination-med-cisplatin-och-gemcitabin-som-foersta-linjens-behandling-av-vuxna-patienter-med-icke-resektabel-eller-metastaserande-urotelcellscancer-3326358?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/eu-kommissionen-godkaenner-bristol-myers-squibbs-opdivo-nivolumab-i-kombination-med-cisplatin-och-gemcitabin-som-foersta-linjens-behandling-av-vuxna-patienter-med-icke-resektabel-eller-metastaserande-urotelcellscancer-3326358?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Thu, 16 May 2024 17:50:37 +0200 https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/nya-laangtidsdata-foer-sotyktu-deukravacitinib-visar-paa-bibehaallen-effekt-och-saekerhet-vid-maattlig-till-svaar-plackpsoriasis-3321950?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/nya-laangtidsdata-foer-sotyktu-deukravacitinib-visar-paa-bibehaallen-effekt-och-saekerhet-vid-maattlig-till-svaar-plackpsoriasis-3321950?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Tue, 07 May 2024 20:56:07 +0200 https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/ema-har-paaboerjat-utredning-av-bms-ansoekan-av-opdivo-och-yervoy-som-foersta-linjens-behandling-av-spridd-tjock-och-aendtarmscancer-3321713?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/ema-har-paaboerjat-utredning-av-bms-ansoekan-av-opdivo-och-yervoy-som-foersta-linjens-behandling-av-spridd-tjock-och-aendtarmscancer-3321713?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Tue, 30 Apr 2024 12:15:57 +0200 https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/positivt-chmp-utlaatande-foer-bristol-myers-squibbs-opdivo-nivolumab-i-kombination-med-cisplatin-och-gemcitabin-som-foersta-linjens-behandling-av-vuxna-patienter-med-icke-resektabel-eller-metastaserande-urotelcellscancer-3320232?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/positivt-chmp-utlaatande-foer-bristol-myers-squibbs-opdivo-nivolumab-i-kombination-med-cisplatin-och-gemcitabin-som-foersta-linjens-behandling-av-vuxna-patienter-med-icke-resektabel-eller-metastaserande-urotelcellscancer-3320232?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Wed, 27 Mar 2024 08:21:33 +0100 Förbättrad överlevnad med Opdivo i kombination med Yervoy hos patienter med avancerad levercellscancer https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/foerbaettrad-oeverlevnad-med-opdivo-i-kombination-med-yervoy-hos-patienter-med-avancerad-levercellscancer-3313365?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/foerbaettrad-oeverlevnad-med-opdivo-i-kombination-med-yervoy-hos-patienter-med-avancerad-levercellscancer-3313365?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Tue, 05 Mar 2024 07:58:00 +0100 Studien CONSIDERING-AF har påbörjats i Halland, med BMS som en samverkande part. Syftet är att undersöka huruvida screening för förmaksflimmer baserat på en riskprediktionsmodell är effektivare än rutinsjukvård för att identifiera individer med förmaksflimmer. Om studien utfaller positivt kan det innebära tidigare upptäckt av förmaksflimmer och att strokeförbyggande behandling kan initieras. https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/bristol-myers-squibb-i-stor-samarbetsstudie-foer-tidig-upptaeckt-av-foermaksflimmer-3307929?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/bristol-myers-squibb-i-stor-samarbetsstudie-foer-tidig-upptaeckt-av-foermaksflimmer-3307929?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Wed, 07 Feb 2024 13:45:35 +0100 https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/subkutan-beredning-med-nivolumab-lika-effektiv-som-intravenoes-opdivo-nivolumab-i-studie-vid-avancerad-eller-metastaserande-njurcellscancer-3302455?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/subkutan-beredning-med-nivolumab-lika-effektiv-som-intravenoes-opdivo-nivolumab-i-studie-vid-avancerad-eller-metastaserande-njurcellscancer-3302455?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Mon, 05 Feb 2024 08:30:00 +0100 https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/aatta-aars-uppfoeljning-av-behandling-med-opdivo-nivolumab-i-kombination-med-yervoy-ipilimumab-fortsaetter-att-visa-oeverlevnadsvinst-jaemfoert-med-sunitinib-hos-patienter-med-njurcellscancer-3301528?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/aatta-aars-uppfoeljning-av-behandling-med-opdivo-nivolumab-i-kombination-med-yervoy-ipilimumab-fortsaetter-att-visa-oeverlevnadsvinst-jaemfoert-med-sunitinib-hos-patienter-med-njurcellscancer-3301528?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Tue, 23 Jan 2024 14:49:40 +0100 https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/dubbel-immunterapi-visar-lovande-resultat-foer-patienter-med-spridd-tjock-och-aendtarmscancer-3298750?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/dubbel-immunterapi-visar-lovande-resultat-foer-patienter-med-spridd-tjock-och-aendtarmscancer-3298750?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Wed, 06 Dec 2023 10:00:57 +0100 NT-rådet rekommenderar Opdivo (nivolumab) i kombination med kemoterapi som neoadjuvant behandling av patienter med kirurgiskt resekterbar icke-småcellig lungcancer. Rekommendationen baseras på resultat från fas III-studien CheckMate-816 som visar att neoadjuvant behandling med Opdivo (nivolumab) i kombination med platinabaserad kemoterapi förbättrade EFS och pCR jämfört med enbart kemoterapi. https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/nt-raadet-rekommenderar-opdivo-nivolumab-i-kombination-med-kemoterapi-som-neoadjuvant-behandling-av-patienter-med-kirurgiskt-resekterbar-icke-smaacellig-lungcancer-3291225?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/nt-raadet-rekommenderar-opdivo-nivolumab-i-kombination-med-kemoterapi-som-neoadjuvant-behandling-av-patienter-med-kirurgiskt-resekterbar-icke-smaacellig-lungcancer-3291225?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Wed, 22 Nov 2023 08:00:00 +0100 https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/bms-staerker-cancervaarden-i-sverige-genom-innovativt-utvecklingsprojekt-tillsammans-med-akademiska-sjukhuset-3287945?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/bms-staerker-cancervaarden-i-sverige-genom-innovativt-utvecklingsprojekt-tillsammans-med-akademiska-sjukhuset-3287945?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb Wed, 01 Nov 2023 08:13:35 +0100 https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/thommen-chacko-utsedd-till-vd-foer-bristol-myers-squibb-i-sverige-3283125?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/bristol-myers_squibb/pressreleases/thommen-chacko-utsedd-till-vd-foer-bristol-myers-squibb-i-sverige-3283125?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Bristol-Myers Squibb